Compare
Bausch Health Companies Inc. vs Vertex Pharmaceuticals Inc vs Viatris Inc vs Regeneron Pharmaceuticals, Inc.
| Latest fiscal year | Bausch Health Companies Inc. BHC | Vertex Pharmaceuticals Inc VRTX | Viatris Inc VTRS | Regeneron Pharmaceuticals, Inc. REGN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $10.27B | $12.00B | $14.30B | $14.34B |
| Revenue growth (YoY) | +6.7% | +8.9% | -3.0% | +1.0% |
| Gross margin | n/a | 86.2% (computed) | 35.1% | n/a |
| Operating margin | 17.7% | 34.8% | -18.6% | 24.9% |
| Net margin | 1.2% | 32.9% | -24.6% | 31.4% |
| Net income | $120.00M | $3.95B | -$3.51B | $4.50B |
| EPS (Diluted) | $0.42 | $15.32 | -$3.00 | $41.48 |
| Operating cash flow | $1.40B | $3.63B | $2.32B | $4.98B |
| Free cash flow | $1.00B | $3.19B | $1.94B | $4.08B |
| Cash & equivalents | $1.31B | $5.08B | $1.32B | $3.12B |
| Total assets | $26.37B | $25.64B | $37.19B | $40.56B |
| Total liabilities | $25.99B | $6.98B | $22.48B | $9.30B |
| Shareholders' equity | $377.00M | $18.67B | $14.71B | $31.26B |
| Return on year-end equity | 31.8% | 21.2% | -23.9% | 14.4% |
| Shares outstanding | 370.53M | 253.99M | n/a | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Bausch Health Companies Inc. | Vertex Pharmaceuticals Inc | Viatris Inc | Regeneron Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $10.27B Ended 2025-12-31 | $12.00B Ended 2025-12-31 | $14.30B Ended 2025-12-31 | $14.34B Ended 2025-12-31 |
| 1 year earlier | $9.62B Ended 2024-12-31 | $11.02B Ended 2024-12-31 | $14.74B Ended 2024-12-31 | $14.20B Ended 2024-12-31 |
| 2 years earlier | $8.76B Ended 2023-12-31 | $9.87B Ended 2023-12-31 | $15.43B Ended 2023-12-31 | $13.12B Ended 2023-12-31 |
| 3 years earlier | $8.12B Ended 2022-12-31 | $8.93B Ended 2022-12-31 | $16.26B Ended 2022-12-31 | $12.17B Ended 2022-12-31 |
| 4 years earlier | $8.43B Ended 2021-12-31 | $7.57B Ended 2021-12-31 | $17.89B Ended 2021-12-31 | $16.07B Ended 2021-12-31 |